Skip to content
Relatix Bio

Relatix Bio

Radically different

  • Services
  • Knowledgebase
  • Partnerships
  • Our Approach
  • Contact
  • About
    • Vision
    • Our mission
    • Privacy Policy
    • FAQ
    • News
Posted on July 8, 2026 by admin
<![CDATA[PP-01 targets CB-1 recovery and dopamine balance, aiming to ease cannabis withdrawal and boost abstinence as a fast-tracked phase 3 trial advances.]]>
CategoriesImported News TagsClinical trial, Fear and threat response, Medication, Mood and emotional regulation

Post navigation

Previous PostPrevious STAT+: In private meeting, Trump officials push to onshore generic drugmaking
Next PostNext Impact of an Artificial Intelligence–Powered Clinical Decision Support System for Acute Kidney Injury Prevention in the Intensive Care Unit: Single-Center Uncontrolled Before-and-After Implementation Study

This is the footer

Privacy Policy Proudly powered by WordPress